Pan-coronavirus vaccine pipeline takes form
Elie Dolgin • April 19, 2022
Dozens of ‘universal’ coronavirus vaccines are in development. But will new technology platforms be able to overcome immunological unknowns?
As debates over additional booster shots for COVID-19 intensify, many public health researchers are looking to the influenza model of vaccination as a guide for how to handle the lasting threat of SARS-CoV-2. That could mean annual shots, as is routine today with seasonal flu prophylaxis.
But just as scientists have long sought a universal flu jab that can provide lasting protection against multiple subtypes of that respiratory virus, so too the field is on the hunt for pan-coronavirus vaccines that can ward off future variants of SARS-CoV-2 and preempt the next pandemic.
Dozens of non-profits, government agencies and vaccine makers have made these candidates a top research priority.
Read more at Nature Reviews Drug Discovery.
Molecular signatures of aging are changing how conservationists assess population health, resilience and risk.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.